Many investors remember that legendary day in September when shares of then little-known biotech Sarepta (SRPT -0.80%) climbed almost 200% in a single day. The promise behind the company's Duchenne muscular dystrophy drug eteplirsen has generated massive interest in the stock and might have some investors thinking that this is a prime buyout target for big pharma players searching for lucrative drugs.
But wait -- is Sarepta actually looking for an acquirer?
In this video, health care analyst Max Macaluso weighs in on the debate and gives his opinion on whether this fledgling biotech will be acquired.
